Literature DB >> 15500137

[Secondary nephrotic syndrome due to collagen disease and vasculitis].

Kazuhito Fukuoka1, Kimimasa Nakabayashi.   

Abstract

The most frequent and representative nephrotic syndrome associated with collagen disease is encountered in patients suffering from lupus nephritis. Lupus nephritis is a glomerulonephritis, which discloses various localizations of immune complexes in the endothelium, mesangium and subepithelium. In addition, vasculitides complicated by nephrotic syndrome also show the deposition of immune complexes in their glomeruli, such as Henoch-Schönlein nephritis and cryoglobulinemic nephritis. The pathogenetic mechanisms of these nephrotic syndromes are explained as follows. The depositions of immune complexes in glomeruli causes proteinuria through a variety of mechanisms. Namely, subendothelial and mesangial immune deposits give capillary and mesangial injuries as well as inflammation that are mediated through activation of complements and cytokines, and subsequently leads to nephrotic-range proteinuria and impairment of renal function. On the other hand, subepithelial and intramembranous deposits disrupt the regulated arrangement of epithelial cells and slit diaphragms, and then disturb the slit diaphragms. The eventual dysfunction of slit diaphragms accordingly progresses to massive proteinuria even without capillary injury. Therefore, nephrotic syndrome associated with collagen disease or vasculitis is usually observed in lupus nephritis or vasculitis related to immune complex depositions, but is not observed in non-immune complex glomerulopathy or vasculopathy.

Entities:  

Mesh:

Year:  2004        PMID: 15500137

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  1 in total

1.  Hepatitis B virus induced cytoplasmic antineutrophil cytoplasmic antibody-mediated vasculitis causing subarachnoid hemorrhage, acute transverse myelitis, and nephropathy: a case report.

Authors:  Utsav Joshi; Roshan Subedi; Bikram Prasad Gajurel
Journal:  J Med Case Rep       Date:  2017-04-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.